The Latest Results of a First-in-class Claudin 18.2-specific Antibody-drug Conjugate will be Announced at the ASCO Plenary Series

November 02, 2023

On November 8, 2023, from 4:00 to 5:00 AM (Beijing Time), Dr. Rui-Hua Xu, professor of Medical Oncology and President of Sun Yat-sen University Cancer Center, will present the latest results regarding the first-in-class anti-claudin 18.2 antibody-drug conjugate for the treatment of advanced Claudin 18.2-positive gastric/gastroesophageal junction (G/GEJ) cancer patients. The presentation will take place during the American Society of Clinical Oncology (ASCO) Plenary Series.

Link to the Online Oral Presentation:

Gastric cancer ranks third in both incidence and mortality among malignancies in China, posing a significant health challenge. Despite recent progress in targeted therapy and genotyping, the effective treatments for advanced G/GEJ cancer remain limited. Currently, only anti-HER2 agents and anti-angiogenic drugs have ventured into clinical evaluations. As a well-established therapeutic target, Claudin 18.2 holds a potential to improve the survival prognosis of advanced gastric cancer patients. 

CMG901, a first-in-class Claudin 18.2-specific antibody-drug conjugate, has previously been granted breakthrough therapy designation by the China National Medical Products Administration (CDE), fast track designation and orphan drug designation by the U.S. Food and Drug Administration (FDA). In this open-label, multicenter Phase I study, CMG901 demonstrated favorable activity in heavily pretreated G/GEJ cancer patients while maintaining a manageable safety profile. This suggested CMG901 as a promising therapeutic option for Claudin 18.2-positive advanced gastric cancer patients.

The ASCO Plenary Series is a monthly online forum for presentation and discussion of the latest cancer research, aiming to advance the most up-to-date treatments for cancer patients. Each monthly program features up to two practice-changing and clinically relevant abstracts on the latest advances in cancer care. This Phase I study has recently garnered significant attention from global experts in this field, making it a presentation not to be missed.

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.